GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biotage AB (OTCPK:BITGF) » Definitions » 5-Year Sharpe Ratio

BITGF (Biotage AB) 5-Year Sharpe Ratio : 0.16 (As of Jul. 18, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Biotage AB 5-Year Sharpe Ratio?

The 5-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past five years. As of today (2025-07-18), Biotage AB's 5-Year Sharpe Ratio is 0.16.


Competitive Comparison of Biotage AB's 5-Year Sharpe Ratio

For the Medical Instruments & Supplies subindustry, Biotage AB's 5-Year Sharpe Ratio, along with its competitors' market caps and 5-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotage AB's 5-Year Sharpe Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biotage AB's 5-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Biotage AB's 5-Year Sharpe Ratio falls into.


;
;

Biotage AB 5-Year Sharpe Ratio Calculation

The 5-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last five years. A stock / portfolio's 5-Year Sharpe Ratio can be calculated by dividing the difference between the five-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past five years.


Biotage AB  (OTCPK:BITGF) 5-Year Sharpe Ratio Explanation

The 5-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past five years. It is calculated as the annualized result of the average five-year monthly excess returns divided by its standard deviation in the five-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Biotage AB 5-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Biotage AB's 5-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotage AB Business Description

Traded in Other Exchanges
Address
Vimpelgatan 5, Box 8, Uppsala, SWE, 751 03
Biotage AB provides separation technology and solutions for analytical and organic chemistry from research to commercial analytical laboratories and industrial applications. Its customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research, and contract manufacturers as well as clinical, forensic, and academic laboratories in addition to organizations focused on food safety, clean water, and environmental sustainability. It serves three geographic markets: The Americas, APAC (Asia-Pacific,) and EMEA (Europe, Middle East & Africa). The company's product areas include Small Molecules & Synthetic Therapeutics, Biologics & Therapeutics, Scale-Up, Diagnostics, Analytical Testing, and Water & Environmental Testing.

Biotage AB Headlines

From GuruFocus

Q3 2024 Biotage AB Earnings Call Transcript

By GuruFocus News 10-24-2024

Biotage moves to the large cap segment

By PRNewswire PRNewswire 01-03-2022

Q3 2023 Biotage AB Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2024 Biotage AB Earnings Call Transcript

By GuruFocus News 02-20-2025

Biotage - Change in number of shares and votes

By PRNewswire PRNewswire 10-29-2021

Biotage AB (publ) Year-End report January - December 2020

By PRNewswire PRNewswire 02-12-2021

KKR Offers to Acquire Biotage AB for $1.2 Billion

By GuruFocus News 04-22-2025